class at each a or d position were sequenced.

- 14. Substitutions were limited to Phe, Leu, Ile, Met, and Val by including an equal mixture of all four bases at the first codon position, T at the second position, and an equal mixture of G and C at the third position.
- 15. The number of standard deviations (Z) between the observed frequency and the expected frequency for a given amino acid at a specific position in a phenotypic class of m members is given as

$$Z = \frac{(f_a - f_b)}{\sigma}$$

where f_a is the observed frequency of the amino acid at the specified position in the given phenotypic class, f_b is the observed frequency in all sequences, and σ , the standard deviation, is calculated as

$$\sigma = \sqrt{mf_b(1 - f_b)}$$

- 16. K. Struhl, Trends Biol. Sci. 14, 137 (1989). K. Struhl and co-workers (personal communication), working with the transcription activation phenotype of GCN4 in yeast, have found that many different amino acids can be substituted for individual leucines in a functional protein.
- 17. In longer coiled coils, such as those found in myosin

and tropomyosin, leucine is found in the d position only 35% of the time (12).

- T. G. Oas, L. P. McIntosh, E. K. O'Shea, F. W. Dahlquist, P. S. Kim, *Biochemistry* 29, 2891 (1990).
 R. Rasmussen *et al.*, unpublished data.
- 20. In constructions similar to those described here, fusions to the helix-loop-helix motif of the myc oncogene product [C. Bunker and R. Kingston, personal communication] and to thyroid hormone receptor [D. Moore, personal communication] also allow dimerization of the NH₂-terminal domain of repressor.
- B. Muller-Hill, L. Crapo, W. Gilbert, Proc. Natl. Acad. Sci. U.S.A. 59, 1259 (1968); I. Herskowitz, Nature 329, 219 (1987).
- 22. The authors wish to thank K. Struhl, R. Kingston, and D. Moore for sharing their results prior to publication; and D. Siegele, A. Grossman, T. Alber, J. Nathans, and the members of the Sauer and Kim labs for their helpful comments and suggestions. Supported by NIH grants (AI15706 to R.T.S. and GM44162 to P.S.K.) and the Lucille P. Markey Charitable Trust. J.C.H. was supported in part by NIH postdoctoral fellowship GM11117. E.K.O. is a Howard Hughes Medical Institute Doctoral Fellow.

7 August 1990; accepted 9 September 1990

Identification of a Specialized Adenylyl Cyclase That May Mediate Odorant Detection

HEATHER A. BAKALYAR AND RANDALL R. REED*

The mammalian olfactory system may transduce odorant information via a G proteinmediated adenosine 3',5'-monophosphate (cAMP) cascade. A newly discovered adenylyl cyclase, termed type III, has been cloned, and its expression was localized to olfactory neurons. The type III protein resides in the sensory neuronal cilia, which project into the nasal lumen and are accessible to airborne odorants. The enzymatic activity of the type III adenylyl cyclase appears to differ from nonsensory cyclases. The large difference seen between basal and stimulated activity for the type III enzyme could allow considerable modulation of the intracellular cAMP concentration. This property may represent one mechanism of achieving sensitivity in odorant perception.

HE VERTEBRATE OLFACTORY SYSTEM detects chemical stimuli in the environment with remarkable specificity and sensitivity. Differences in molecular structure as subtle as stereochemical configuration are discernible, and the threshold of sensitivity for some airborne odorants is in the range of parts per trillion (1). At least some odorants stimulate a guanosine triphosphate (GTP)-dependent increase in cAMP in the olfactory cilia, which are specialized structures that project from the apical dendrites of the olfactory sensory neurons (2). Adenylyl cyclase activity, which is high in olfactory tissue, is enriched in these sensory neurons (2, 3). The neuronal cilia also have nonspecific cation channels, which open in response to increasing cyclic nucleotide concentrations (4). These results, taken together, suggest that olfactory signal transduction involves an odorant-stimulated second messenger cascade that leads to sensory neuron depolarization and initiation of an action potential.

Several components of the odorant transduction pathway have evolved olfactoryspecific variants. For example, the α subunit of G_{olf} which resembles the α subunit of the stimulatory G protein, G_s, is found exclusively in olfactory neuronal cilia (5). A cyclic nucleotide-activated cation channel has been identified, and its mRNA has been shown to be confined to olfactory neurons (6). Similarly, it is possible that an olfactoryspecific adenylyl cyclase exists that contributes to the high enzyme activity seen in olfactory cilia (3, 7). With a monoclonal antibody that recognizes the Ca²⁺/calmodulin-sensitive cyclase in brain, an adenylyl cyclase species has been detected in olfactory cilia that is distinct in molecular size from

the brain form of the enzyme (7).

The molecular cloning of the brain-specific type I enzyme (8) has allowed us to isolate cDNA clones encoding an adenylyl cyclase that may play an effector role in olfaction. A rat olfactory cDNA library was probed with an oligonucleotide based on the sequence of a tryptic fragment of purified type I adenylyl cyclase from bovine brain (9). By this method, we isolated a single class of cDNA clones that encoded an adenylyl cyclase (type II) (6) distinct from the type I enzyme. The mRNAs that encode the type I and type II enzymes were expressed in high concentrations in brain but were undetectable or present in low amounts in olfactory tissue. The olfactory cDNA library was therefore screened again at low stringency (10) with the coding region from the cDNAs for both the type I and type II adenylyl cyclases. A distinct class of clones was identified that weakly hybridized to both of the previously identified forms. Approximately one in every 1000 recombinant cDNA clones from the rat olfactory cDNA library represented this type III adenylyl cyclase.

We obtained the nucleotide and deduced amino acid sequences of the cDNA that encoded type III adenylyl cyclase (Fig. 1) (11). A potential initiation codon at position -173 is followed by stop codons in three reading frames. The methionine codon at nucleotide +1 is contained within a canonical eukaryotic translation initiation sequence (12) and is followed by an open reading frame that encodes 1144 amino acids.

Type III adenylyl cyclase appears to be topographically similar to the 1134-amino acid type I enzyme (8). A comparison of the hydropathy profiles for both proteins (Fig. 2A) revealed that each protein has two extremely hydrophobic regions: one near the NH₂-terminus and the second between amino acid residues 600 and 850. The hydrophobic regions of the type III protein each contain six potential membrane-spanning segments in a pattern analogous to that predicted for the bovine brain type I cyclase, suggesting a similar orientation in the membrane. The type I enzyme, which is glycosylated, contains a consensus sequence for N-linked carbohydrate addition between membrane-spanning regions 9 and 10 on the putative extracellular face of the molecule (8). The type III protein also has a potential N-glycosylation site between transmembrane regions 9 and 10, and biochemical evidence confirmed that this protein is a substrate for N-linked glycosylation (Fig. 3B). Treatment of olfactory cilia with peptide:N-glycosidase F (PNGaseF) altered the mobility of the protein, from that corre-

Department of Molecular Biology and Genetics, The Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205.

^{*}To whom correspondence should be addressed.

1	MTEDQGFSDP	EYSAEYSAEY	SVSLPSDPDR	GVGRTHEISV	RNSGSCLCLP	RFMRLTFVPE	SLENLYQTYF	KRQRHETLLV	80	
81	LVVFAALFDC	YVVVMCAVVF	SSDKLAPLMV	AGVGLVLDII	LFVLCKKGLL	PDRVSRKVVP	YLLWLLITAQ	IFSYLGLNFS	160	
161	RAHAASDTVG	WQAFFVFSFF	ITLPLSLSPI	VIISVVSCVV	HTLVLGVTVA	QQQQDELEGM	QLLREILANV	FLYLCAIIVG	240	
241	IMSYYMADRK	HRKAFLEARQ	SLEVKMNLEE	QSQQQENLML	SILPKHVADE	MLKDMKKDES	QKDQQQFNTM	YMYRHENVSI	320	
321	LFADIVGFTQ	LSSACSAQEL	VKLLNELFAR	FDKLAAKYHQ	LRIKILGDCY	YCICGLPDYR	EDHAVCSILM	GLAMVEAISY	400	
401	VREKTKTGVD	MRVGVHTGTV	LGGVLGQKRW	QYDVWSTDVT	VANKMEAGGI	PGRVHISQST	MDCLKGEFDV	EPGDGGSRCD	480	
481	YLDEKGIETY	LIIASKPEVK	KTAQNGLNGS	ALPNGAPASK	PSSPALIETK	EPNGSAHASG	STSEEAEEQE	AQADNPSFPN	560	
561	PRRRLRLQDL	ADRVVDASED	EHELNQLLNE	ALLERESAQV	VKKRNTFLLT	MRFMDPEMET	RYSVEKEKQS	GAAFSCSCVV	640	
641	LFCTAMVEIL	IDPWLMTNYV	TFVVGEVLLL	ILTICSMAAI	FPRAFPKKLV	AFSSWIDRTR	WARNTWAMLA	IFILVMANVV	720	
721	DMLSCLQYYM	GPYNVTTGIE	LDGGCMENPK	YYNYVAVLSL	IATIMLVQVS	HMVKLTLMLL	VTGAVTAINL	YAWCPVFDEY	800	
801	DHKRFQEKDS	PMVALEKMQV	LSTPGLNGTD	SRLPLVPSKY	SMTVMMFVMM	LSFYYFSRHV	EKLARTLFLW	KIEVHDQKER	880	
881	VYEMRRWNEA	LVTNMLPEHV	ARHFLGSKKR	DEELYSQSYD	EIGVMFASLP	NFADFYTEES	INNGGIECLR	FLNEIISDFD	960	
961	SLLDNPKFRV	ITKIKTIGST	YMAASGVTPD	VNTNGFTSSS	KEEKSDKERW	QHLADLADFA	LAMKDTLTNI	NNQSFNNFML	1040	
1041	RIGMNKGGVL	AGVIGARKPH	YDIWGNTVNV	ASRMESTGVM	GNIQVVEETQ	VILREYGFRF	VRRGPIFVKG	KGELLTFFLK	1120	
1121	GRDRPAAFPN	GSSVTLPHQV	VDNP						1144	

Fig. 1. The amino acid sequence of type III adenylyl cyclase (128,852 daltons) predicted from clone pROCS6+10, which includes 366 nucleotides 5' to the presumed initiating ATG codon and 742 nucleotides 3' to the TGA stop codon at position 3432. The GenBank accession number for the nucleotide sequence is M55075. A potential site for N-glycosylation (13) between predicted transmembrane spans 9 and 10 is at amino acid residue 734. Abbreviations for the amino acid residues are: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.

sponding to an apparent molecular size of 200 kd (7) to a mobility consistent with the calculated molecular size of 129 kd. Two additional potential sites for glycosylation are present on the predicted extracellular face of the type III protein (13).

A dot matrix alignment of the type III and type I enzymes revealed that the region of greatest similarity between the two proteins is within the putative intracellular domains (Fig. 2B). These regions show great similarity to a region of the atrial naturetic factor receptor responsible for guanosine 3'-5'monophosphate (cGMP) formation (8). These domains in the mammalian adenylyl cyclases also share modest similarity with the catalytic region of yeast adenvlyl cyclase, a protein whose functional domains have been characterized by genetic and biochemical analyses (8, 14). The regions with membrane-spanning potential are the least well conserved between the two mammalian adenylyl cyclases, perhaps suggesting a structural rather than a sequence-specific function for these hydrophobic domains.

The tissue distribution of the type III adenylyl cyclase mRNA was examined by Northern analysis (Fig. 4A). RNA isolated from seven tissues, including two epithelial tissues (lung and intestine), was hybridized to the coding region from the type III cDNA; the results indicated that expression of the type III mRNA was limited to olfactory epithelium. To assess the distribution of type III mRNA among the cell types within the olfactory epithelium, we used a neuronal depletion technique. The sensory neurons of the olfactory epithelium degenerate 6 to 8 days after the removal of their target tissue, the olfactory bulb (15). Type III adenylyl cyclase mRNA disappeared concomitant with the loss of sensory neurons after bulbectomy (Fig. 4B).

The localization of the type III protein within olfactory sensory neurons was examined by immunohistochemical analysis (Fig. 5). Only cilia, the sensory apparatus of the olfactory neurons, were stained with an antibody to a peptide sequence specific to the type III adenylyl cyclase (16). At the nasal septum of a unilaterally bulbectomized rat, where normal and neuron-depleted epithelium can be seen in the same field, no staining was detected on the denervated side. Electron microscopic examination of normal rat olfactory epilthelia demonstrated that immunoreactivity was confined to ciliary





After addition of gel-loading buffer (24), a portion of each sample (15 μ g of protein) was subjected to SDS-polyacrylamide gel electrophoresis (8% acrylamide gel). The separated proteins were subsequently transferred to Immobilon (Millipore). The untreated lane contained 15 μ g of olfactory ciliary protein (25). Type III protein was detected with purified anti-HAB-1 (16, 26) diluted 1:100 and visualized with ¹²⁵I-labeled protein A. The positions of molecular mass standards are indicated.

structures (17). This localization is nearly identical with that seen for G_{olf} and suggests that these two components may interact at this site to mediate olfaction.

The biochemical properties of type III adenylyl cyclase were examined in a heterologous system. The cDNA encoding type III adenylyl cyclase was expressed under the control of the cytomegalovirus promoter (18) in a human kidney cell line (293 cells) that has low endogenous cyclase activity. Cell homogenates from stably transformed clonal lines were assayed for adenylyl cyclase activity. Production of cAMP was measured under basal conditions; in the presence of forskolin, a direct activator of adenylyl cyclase; and in the presence of AlF₄⁻, which indirectly modulates adenylyl cyclase





Fig. 2. (A) Hydropathy profiles of type III olfactory adenylyl cyclase and type I brain adenylyl cyclase. Shaded areas indicate putative membrane-spanning regions. The Strider 1.1 DNA analysis software was used to calculate the hydrophobic indices by the method of Kyte and Doolittle (22), averaging over a window size of nine amino acid residues. (B) Dot matrix comparison of type III adenylyl cyclase with type I adenylyl cyclase. Regions of high amino acid similarity between the two enzymes were located by the MacVector software (IBI) and the pam250 scoring matrix. Window size for the comparison was eight amino acids, and the stringency of match identities was set at 60%.



Fig. 4. Northern analysis of the tissue distribution type III adenylyl cyclase mRNA. (**A**) Total RNA (12.5 μ g) isolated from seven rat tissues (27, 28). (**B**) Total RNA (10 μ g) derived from normal rat olfactory epithelium or neuron-depleted epithelium (5). Previous hybridization of both blots with ³²P-labeled tubulin cDNA suggested each lane contained similar amounts of total RNA. Hybridization of the filter in (B) with ³²P-labeled cDNA for olfactory marker protein, a mature olfactory neuron marker, confirmed the loss of olfactory sensory neurons in the neuron-depleted olfactory epithelium. The autoradiograms shown were exposed for 14 hours at -80° C.

through G protein activation. In the presence of forskolin (100 μ M) (19), adenylyl cyclase activity of cell lines that expressed the type I and type III enzymes was five to six times that of control cells (Fig. 6). In addition, the increase in adenylyl cyclase activity in extracts of type III cDNA–transfected cells in response to AlF₄⁻ was greater than that seen in control cell homogenates. These results indicate that the endogenous G_s protein present in the 293 cell line can activate type III adenylyl cyclase. Previous experiments have shown that G_{olf}, which shares 88% amino acid identity with G_s, is able to interact with the adenylyl cyclase present in





reaction. The following substances were included as indicated: 100 μ M forskolin (striped bars), AlF₄⁻ (20 μ M AlCl₃ + 10 mM NaF) (open bars), or no additions (solid bars). After 45 min at 31°C, the reactions were stopped with 200 μ l of 2% SDS, and cAMP formation was assessed (*31*). Assays of transiently transfected 293 cells demonstrated similar results (type I basal activity equals 19.4 ± 1.3 pmol min⁻¹ per milligram of protein, type I forskolin activity equals 252.8 ± 53.0 pmol min⁻¹ per milligram of protein; type III basal activity equals 2.9 ± 1.0 pmol min⁻¹ per milligram of protein; type III forskolin activity equals 2.4 ± 0.2 pmol min⁻¹ per milligram of protein; pCIS forskolin activity equals 169.6 ± 17.0 pmol min⁻¹ per milligram of protein), although the forskolin-activities of type III and type I cDNA–transfected lines was only two- to threefold that of control cells, compared to the five- to sixfold enhancement observed on the stable lines.

the S49 cyc^- mouse cell line (5, 20). Olfactory cilia preparations have high adenylyl cyclase activity, apparently resulting from activated G proteins present in the absence of exogenous odorant (2). The detailed characterization of the interaction between type III cyclase and G_{olf} will require the reconstitution of purified components.

The type III and type I cDNA-transfected cell lines showed similar responses to forskolin and AlF_4^- . We expected that the increased amounts of adenylyl cyclase present in these cell lines, demonstrated by forskolin activation, would also be reflected in an increased basal activity. Whereas an increased basal activity was observed in ho-

Fig. 5. Subcellular localization of type III adenylyl cyclase. Olfactory tissue from a unilaterally bulbectomized rat was embedded in paraffin, and immunocytochemistry was performed with the use of Vectastain ABC rabbit IgG (immunoglobulin G) kit (Vector Labs). Dewaxed sections were blocked with 2% normal goat serum in phosphate-buffered saline (PBS), and incubated at room temperature with affinity-purified antisera to HAB-1 (a-



ti-HAB-1) (16, 26) diluted 1:100 with PBS. Secondary antibody was used at 1:200 dilution and visualized with diaminobenzidine and ABC-horseradish peroxidase. Prior incubation of the antisera with an excess of HAB-1 peptide eliminated staining. (A) Photograph taken at an optical magnification of $200 \times$ of anti-HAB-1 staining through the nasal septum of a unilaterally bulbectomized rat. (B) Photograph taken at an optical magnification of $1000 \times$ of normal olfactory epithelium. ES, epithelial surface; N, neuron-containing normal epithelium; D, neuron-depleted epithelium. The cilia in this preparation collapsed during the embedding process. BL, basal lamina; BV, blood vessel; AX, axon bundle.

7 DECEMBER 1990

mogenates from cells expressing the type I enzyme (125.6 \pm 8.8 pmol min⁻¹ per milligram of protein), the basal adenylyl cyclase activity of the type III enzyme–expressing cell line (4.7 \pm 0.1 pmol min⁻¹ per milligram of protein) was similar to that seen for control cells (4.0 \pm 0.3 pmol min⁻¹ per milligram of protein) (21). Expression of the nonsensory type II adenylyl cyclase in this system also led to markedly increased basal activity (6).

The large difference seen between basal and stimulated activity for the type III enzyme could allow considerable modulation of the intracellular cAMP concentration. In the absence of stimulatory ligand, low amounts of cAMP could be maintained even in an environment where the adenylyl cyclase protein is highly concentrated. On activation of adenylyl cyclase, the combination of an abundance of enzyme and the large surface-to-volume ratio in cilia would allow a rapid increase in cAMP concentration. The dynamic modulation of cAMP concentration afforded by the enzymatic properties of the type III cyclase could contribute to the sensitivity in odorant detection that is characteristic of this sensory system.

REFERENCES AND NOTES

- M. G. J. Beets, in Fragrance Chemistry: The Science of Sense and Smell, E. T. Theimer, Ed. (Academic Press, New York, 1982), pp. 77–122.
 U. Pace, E. Hanski, Y. Salomon, D. Lancet, Nature
- U. Pace, E. Hanski, Y. Salomon, D. Lancet, Nature 316, 255 (1986); P. Sklar, R. R. Anholt, S. H. Snyder, J. Biol. Chem. 261, 15538 (1986); H. Breer, I. Boekhoff, E. Tareilus, Nature 345, 65 (1990).
- 3. D. T. Jones, E. Barbosa, R. R. Reed, Cold Spring Harbor Symp. Quant. Biol. 53, 349 (1988).

REPORTS 1405

- 4. T. Nakamura and G. H. Gold, Nature 325, 442 (1987)
- 5. D. T. Jones and R. R. Reed, Science 244, 790 (1989).
- 6. R. R. Reed, unpublished data.
- K. R. Rett, unpublication and an environment of the second second
- tide probe derived from a tryptic fragment of the bovine brain type I adenylyl cyclase was used as described (8). Recombinant phage (200,000) from a rat olfactory oligo(dT)-primed \lambda gt10 library were screened (28).
- 10. Low stringency wash conditions: twice for 20 min in 2× SSC (standard saline citrate) at 55°C
- 11. The complete cDNA of the rat type III adenylyl cyclase was obtained by ligation of two clones. Clone pROSC10-4 (nucleotides -366 to +3183) and clone pROSC6-4 (nucleotides 465 to 4167) were fused at an overlapping Bst EII site at nucleotide 3038 to generate the complete pROSC6+10 construct.
- 12. M. Kozak, Nucleic Acids Res. 15, 8125 (1987).
- 13. Other potential sites for N-glycosylation that are predicted to reside on the extracellular face of the type III protein are located at amino acid residues 158 and 827. Additional N-linked glycosylation consensus sequences exist in the large putative intracellular domains, which are similar to the catalytic domains of yeast adenylyl cyclase.14. T. Kataoka, D. Broek, M. Wigler, Cell 43, 493
- (1985); P. Masson, G. Lenzen, J. M. Jacquemin, A. Danchin, Curr. Genet. 10, 343 (1986); M. S. Marshall, J. B. Gibbs, E. M. Scolnick, I. S. Sigal, Mol. Cell. Biol. 8, 52 (1988); J. Field et al., Science 247, 464 (1990).
- 15. G. A. M. Graziadei and P. P. C. Graziadei, J. Neurocytol. **8**, 197 (1979)
- 16. HAB-1 peptide, H₂N-YPNGSSVTLPHQVVDNP-COOH, was coupled to bovine serum albumin carrier with glutaraldehyde (32) and used to generate polyclo-nal antisera in rabbit. This peptide sequence is found at the COOH-terminus of type III adenylyl cyclase, and is not found in any other sequenced adenylyl cyclases.
- B. Menco, personal communication.
 C. M. Gorman, D. R. Gies, G. McCray, DNA and Protein Engineering Techniques 2, 3 (1990); D. B. Diction Engineering Science 1202 (1998). Pritchett *et al.*, *Science* 242, 1306 (1988).
 19. K. B. Seamon, W. Padgett, J. W. Daly, *Proc. Natl.*

- Acad. Sci. U.S.A. 78, 3363 (1981).
 D. T. Jones, S. B. Masters, H. R. Bourne, R. R. Reed, J. Biol. Chem. 265, 2671 (1990).
 The basal activity for the type I cDNA-transfected 293 cells appeared to be G protein independent. This activity use not reduced with the addition of This activity was not reduced with the addition of β -thioguanosine diphosphate (100 $\mu M)$ to the assay mixture (H. Bakalyar, unpublished data). 22. J. Kyte and R. F. Doolittle, J. Mol. Biol. 157, 105
- (1982).
- 23. The activity of the PNGaseF preparation was such that 1 µl will completely cleave the N-linked sugars from 100 µg of ovalbumin in 60 min at 37°C.
- U. K. Laemmli, *Nature* 227, 680 (1970). C. D. Rhein and R. H. Cagan, *Proc. Natl. Acad. Sci.*
- 25. U.S.A. 77, 4412 (1980).
- 26. Antigen purification of sera was performed as described (32). HAB-1 peptide was coupled to Affigel-10 matrix (Bio-Rad) by adding peptide (10 mg) in 10 ml of 0.5 M NaCl and 0.1 M NaHCO₃ to 3 ml of Affigel-10 slurry that had been washed with 1 mM HCl. Resin was incubated on a rotator at room temperature for 30 min. Ethanolamine (1 ml of a 1 M solution) was added and the mixture incubated for 5 min. The peptide-coupled beads were washed on sintered glass and stored at 4°C in 50 mM sodium phosphate (pH 7.0) and 0.1% sodium azide.
- 27. Samples were treated with glyoxal and separated on a 1% agarose gel as described (28). The fractionated material was transferred to nitrocellulose and prehybridized at 42° C in 50% formamide, 6× SSPE (saline, sodium phosphate, EDTA), 5× Denhardt's solution, 0.1% SDS, and single-stranded DNA (100 μ g/ml). The Eco RI fragment representing the full-length type III cDNA was labeled with ³²P and hybridized to the immobilized RNA samples for 48 hours at 42°C. Filters were washed once for 15 min

in $1 \times$ SSC and 0.1% SDS at 25°C, and then twice for 20 min in 1× SSC and 0.1% SDS at 65°C

- 28. D. T. Jones and R. R. Reed, J. Biol. Chem. 262, 14241 (1987).
- The complete pROSC6+10 cDNA coding region 29 was cloned into the polylinker site of pCIS (18). Neomycin-resistant stable lines were produced by introduction (30) of pSVneo (0.5 μ g) and adenylyl cyclase type I or type III cDNA expression plasmids (5 µg) or the pCIS vector control into 100-mm culture dishes that contained human kidney 293 cells at ~50% confluency. After 24 hours, G418 (500 μ g/ml) was added in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 µg/ml). ~3 weeks, viable clones were transferred to After individual dishes and expanded. Adenylyl cyclase assays were performed on each of the clonal cell lines. Forskolin-stimulated activity revealed that one line expressed the type I enzyme and four lines

expressed the type III enzyme. Five G418-resistant lines were characterized from transfections with the pSVneo and the pCIS control vectors.

- P. J. Southern and P. Berg, J. Mol. Applied Genet. 1, 30 327 (1982).
- 31. Y. Salomon, in Advances in Cyclic Nucleotide Research, G. Brooker, P. Greengard, G. A. Robison, Eds. (Raven Press, NY, 1979), vol. 10, pp. 35–55. E. Harlow and D. Lane, *Antibodies: A Laboratory*
- 32. Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988).
- We thank our colleagues for helpful discussions; P. 33. G. Feinstein for valuable contributions; HHMI-JHU Biopolymer Facility for synthetic oligonucleotides and oligopeptide; G. Hart for PNGaseF; and Genentech for the mammalian expression vector. Supported by NIH grant 5T32CA09339 (to H.A.B.).

5 June 1990; accepted 21 August 1990

Isotope-Edited NMR of Cyclosporin A Bound to Cyclophilin: Evidence for a Trans 9,10 Amide Bond

S. W. FESIK,* R. T. GAMPE, JR., T. F. HOLZMAN, D. A. EGAN, R. Edalji, J. R. Luly, R. Simmer, R. Helfrich, V. Kishore, D. H. RICH

The binding of a ¹³C-labeled cyclosporin A (CsA) analog to cyclophilin (peptidyl prolyl isomerase) was examined by means of isotope-edited nuclear magnetic resonance (NMR) techniques. A trans 9,10 peptide bond was adopted when CsA was bound to cyclophilin, in contrast to the cis 9,10 peptide bond found in the crystalline and solution conformations of CsA. Furthermore, nuclear Overhauser effects (NOEs) were observed between the ζ_3 and ε_3 protons of the methylleucine (MeLeu) residue at position 9 of CsA and tryptophan¹²¹ (Trp¹²¹) and phenylalanine (Phe) protons of cyclophilin, suggesting that the MeLeu⁹ residue of CsA interacts with cyclophilin. These results illustrate the power of isotope-edited NMR techniques for rapidly providing useful information about the conformations and active site environment of inhibitors bound to their target enzymes.

YCLOSPORIN A (CSA) IS A CYCLIC undecapeptide (Fig. 1) that is widely used as an immunosuppressive agent in organ transplantation (1). Although its precise mechanism of action is unknown, the immunosuppressive activity of CsA may be linked to its affinity for the protein cyclophilin (molecular mass ~17.8 kD), because the binding to cyclophilin appears to correlate with the relative immunosuppressive activities of CsA analogs (2-4). Recently, cyclophilin was shown (5, 6) to have the same amino acid sequence as peptidyl prolyl isomerase, an enzyme that catalyzes the cis-trans isomerization of Xaaproline peptide bonds (where Xaa is any amino acid). Cyclosporin A was found to be

Pharmaceutical Discovery Division, Abbott Laborato-ries, Abbott Park, IL 60064. V. Kishore and D. H. Rich, School of Pharmacy and Department of Chemistry, University of Wisconsin– Madison, Madison, WI 53706.

a potent inhibitor of this enzyme, suggesting that some of the biological effects of CsA (7) may be mediated by blocking the enzymatic activity of cyclophilin (8, 9).

In order to aid in the design of CsA analogs with reduced toxicity and potentially greater clinical utility, structural information on the binding of CsA to cyclophilin is desired. To date, however, only the conformation of CsA by itself has been determined in the crystalline state by x-ray crystallography and in apolar solvents by NMR spectroscopy (10). In three different crystal forms of CsA involving different intermolecular contacts and in two different solvent systems (10, 11), CsA was found to adopt an antiparallel β-pleated sheet consisting of residues $11 \rightarrow 7$ with a type-II' β -turn at residues $2 \rightarrow 5$. The remaining residues (8 to 10) form a loop defined by a *cis* peptide bond between MeLeu residues 9 and 10. The only differences in the crystal and solution conformations are in the orientation of the 1-MeBmt [(4R)-N-methyl-4-butenyl-4-

S. W. Fesik, R. T. Gampe, Jr., T. F. Holzman, D. A. Egan, R. Edalji, J. R. Luly, R. Simmer, R. Helfrich, Pharmaceutical Discovery Division, Abbott Laborato-

^{*}To whom correspondence should be addressed.